Two of Bambusa’s bispecific antibody candidates for immunological and inflammatory disorders are set to enter the clinic in ...

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia ...

Innovative Bispecific Antibody Therapies in Cancer Treatment Emerge as Patent Filings SurgeDublin, Feb. 18, 2025 (GLOBE NEWSWIRE) -- The "Bispecific Antibody & Cancer Patent Landscape Analysis" report ...

Context will also participate in one-on-one meetings at each of the above conferences.

Explore how T cell engagers could transform cancer and autoimmune treatments through promising trials and key collaborations.

Tecvayli (teclistamab) is an off-the-shelf bispecific antibody targeting both BCMA and CD3 which is also under review at the FDA and if approved will slot into J&J's myeloma therapy portfolio ...

Teclistamab is a companion bispecific to J&J's talquetamab, a bispecific antibody that binds to CD3 and GPRC5D, a novel myeloma target. Both bispecifics have arisen out of J&J's longstanding ...

Experts said a certain type of bispecific antibody seems to have hit upon a crucial combination of two cancer targets: the proteins VEGF and either PD-1 or PD-L1. “It’s exactly that,” said ...

Tiziana Life Sciences Ltd., which is developing the intranasal fully human anti-CD3 monoclonal antibody foralumab for neurological indications, has reported results from studies using a nasal anti-CD3 ...

Linvoseltamab is an investigational B-cell maturation antigen CD3-targeted bispecific antibody. The BLA resubmission was needed as the original application could not be approved due to manufacturing ...